CY1116143T1 - Παραγωγα χρωμενονης με αντικαρκινικη δραση - Google Patents

Παραγωγα χρωμενονης με αντικαρκινικη δραση

Info

Publication number
CY1116143T1
CY1116143T1 CY20151100157T CY151100157T CY1116143T1 CY 1116143 T1 CY1116143 T1 CY 1116143T1 CY 20151100157 T CY20151100157 T CY 20151100157T CY 151100157 T CY151100157 T CY 151100157T CY 1116143 T1 CY1116143 T1 CY 1116143T1
Authority
CY
Cyprus
Prior art keywords
chromenone derivatives
cancer action
chromenone
derivatives
cancer
Prior art date
Application number
CY20151100157T
Other languages
Greek (el)
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Der Brempt Christine Marie Paul Lambert-Van
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1116143T1 publication Critical patent/CY1116143T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20151100157T 2009-10-27 2015-02-13 Παραγωγα χρωμενονης με αντικαρκινικη δραση CY1116143T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27
EP10769052.1A EP2493870B1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti -tumour activity

Publications (1)

Publication Number Publication Date
CY1116143T1 true CY1116143T1 (el) 2017-02-08

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100157T CY1116143T1 (el) 2009-10-27 2015-02-13 Παραγωγα χρωμενονης με αντικαρκινικη δραση

Country Status (41)

Country Link
US (5) US8399460B2 (cg-RX-API-DMAC7.html)
EP (1) EP2493870B1 (cg-RX-API-DMAC7.html)
JP (2) JP5657010B2 (cg-RX-API-DMAC7.html)
KR (1) KR101738195B1 (cg-RX-API-DMAC7.html)
CN (2) CN104447657B (cg-RX-API-DMAC7.html)
AR (1) AR078786A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010311107B9 (cg-RX-API-DMAC7.html)
BR (1) BR112012010124B8 (cg-RX-API-DMAC7.html)
CA (1) CA2776994C (cg-RX-API-DMAC7.html)
CL (1) CL2012001056A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541528A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120217A (cg-RX-API-DMAC7.html)
CU (1) CU20120069A7 (cg-RX-API-DMAC7.html)
CY (1) CY1116143T1 (cg-RX-API-DMAC7.html)
DK (1) DK2493870T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000124A (cg-RX-API-DMAC7.html)
EA (1) EA020523B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011838A (cg-RX-API-DMAC7.html)
ES (1) ES2530943T3 (cg-RX-API-DMAC7.html)
GT (1) GT201200126A (cg-RX-API-DMAC7.html)
HN (1) HN2012000889A (cg-RX-API-DMAC7.html)
HR (1) HRP20150146T1 (cg-RX-API-DMAC7.html)
IL (1) IL219191A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03328A (cg-RX-API-DMAC7.html)
ME (1) ME02050B (cg-RX-API-DMAC7.html)
MX (1) MX2012005027A (cg-RX-API-DMAC7.html)
MY (1) MY179833A (cg-RX-API-DMAC7.html)
NI (1) NI201200081A (cg-RX-API-DMAC7.html)
NZ (1) NZ599457A (cg-RX-API-DMAC7.html)
PE (1) PE20130149A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500804A1 (cg-RX-API-DMAC7.html)
PL (1) PL2493870T3 (cg-RX-API-DMAC7.html)
PT (1) PT2493870E (cg-RX-API-DMAC7.html)
RS (1) RS53813B1 (cg-RX-API-DMAC7.html)
SA (1) SA110310808B1 (cg-RX-API-DMAC7.html)
SI (1) SI2493870T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500036B (cg-RX-API-DMAC7.html)
TW (1) TWI483939B (cg-RX-API-DMAC7.html)
UA (1) UA107474C2 (cg-RX-API-DMAC7.html)
UY (1) UY32978A (cg-RX-API-DMAC7.html)
WO (1) WO2011051704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
CA2897279C (en) 2013-01-23 2020-12-29 Astrazeneca Ab Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
US9763950B2 (en) * 2013-03-04 2017-09-19 Astrazeneca Ab Combination treatment
NZ726055A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
CA2952044C (en) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
SG11201610095SA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN106660994A (zh) 2014-06-13 2017-05-10 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN108349946B (zh) * 2015-10-09 2021-05-18 詹森药业有限公司 作为PI3Kβ抑制剂的喹喔啉和吡啶并吡嗪衍生物
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
WO2022164812A1 (en) * 2021-02-01 2022-08-04 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
WO2022235575A1 (en) * 2021-05-03 2022-11-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
BR112023022940A2 (pt) * 2021-05-03 2024-01-23 Petra Pharma Corp Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
JP7702057B2 (ja) * 2021-05-27 2025-07-03 ペトラ・ファーマ・コーポレイション がんの治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
CA3232906A1 (en) * 2021-10-07 2023-04-13 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof
US20250136568A1 (en) * 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
WO2025026442A1 (zh) * 2023-08-02 2025-02-06 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
RU2118321C1 (ru) 1988-12-21 1998-08-27 Дзе Апджон Компани Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
CN1891693A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
JP4646626B2 (ja) * 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド3−キナーゼβの阻害
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
CN101506211B (zh) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
KR20120098724A (ko) 2012-09-05
PL2493870T3 (pl) 2015-04-30
UA107474C2 (uk) 2015-01-12
US8673906B2 (en) 2014-03-18
ECSP12011838A (es) 2012-06-29
WO2011051704A1 (en) 2011-05-05
ME02050B (me) 2015-05-20
IL219191A0 (en) 2012-06-28
JP2015078202A (ja) 2015-04-23
PE20130149A1 (es) 2013-03-10
DK2493870T3 (en) 2015-02-23
SMT201500036B (it) 2015-05-05
CN102712615A (zh) 2012-10-03
HK1206335A1 (zh) 2016-01-08
CA2776994A1 (en) 2011-05-05
BR112012010124B1 (pt) 2021-02-17
AU2010311107A1 (en) 2012-05-03
PT2493870E (pt) 2015-02-18
HK1174027A1 (en) 2013-05-31
UY32978A (es) 2011-05-31
HN2012000889A (es) 2015-08-03
EP2493870B1 (en) 2014-12-17
US20110098271A1 (en) 2011-04-28
NI201200081A (es) 2012-11-07
CN102712615B (zh) 2014-12-17
CO6541528A2 (es) 2012-10-16
US8399460B2 (en) 2013-03-19
US9029374B2 (en) 2015-05-12
MY179833A (en) 2020-11-17
JP5657010B2 (ja) 2015-01-21
CL2012001056A1 (es) 2012-10-05
TWI483939B (zh) 2015-05-11
AU2010311107B2 (en) 2014-03-27
IN2012DN03328A (cg-RX-API-DMAC7.html) 2015-10-23
NZ599457A (en) 2014-04-30
US9718800B2 (en) 2017-08-01
HRP20150146T1 (hr) 2015-05-22
BR112012010124B8 (pt) 2021-05-25
US20160272607A1 (en) 2016-09-22
ES2530943T3 (es) 2015-03-09
KR101738195B1 (ko) 2017-05-19
RS53813B1 (sr) 2015-06-30
DOP2012000124A (es) 2012-07-15
TW201121960A (en) 2011-07-01
CA2776994C (en) 2017-10-31
GT201200126A (es) 2014-03-03
SA110310808B1 (ar) 2013-11-24
CN104447657A (zh) 2015-03-25
CU20120069A7 (es) 2012-10-15
MX2012005027A (es) 2012-09-07
PH12012500804A1 (en) 2022-10-03
CR20120217A (es) 2012-06-28
JP5872016B2 (ja) 2016-03-01
JP2013508449A (ja) 2013-03-07
US20130158026A1 (en) 2013-06-20
US20160060240A1 (en) 2016-03-03
EA201200618A1 (ru) 2012-12-28
BR112012010124A2 (pt) 2016-06-07
US20140194419A1 (en) 2014-07-10
SI2493870T1 (sl) 2015-03-31
AU2010311107B9 (en) 2014-06-19
AR078786A1 (es) 2011-11-30
EA020523B1 (ru) 2014-11-28
EP2493870A1 (en) 2012-09-05
EA020523B9 (ru) 2015-01-30
CN104447657B (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
CY1116143T1 (el) Παραγωγα χρωμενονης με αντικαρκινικη δραση
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
JO3674B1 (ar) مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
CU20110208A7 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
CY1117792T1 (el) Ανταγωνιστες toy trpv4
EA201590862A1 (ru) Фармацевтические композиции
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
MX2015004362A (es) Derivados de ketamina.
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor